anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: CID 163285897
Trial phase: Phase 3
ATC code: A10BX16
SMILES: CCC(C)C(NC(=O)C(CC(C)C)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(C)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)C(CCC(N)=O)NC(=O)C(C)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(NC(=O)C(CO)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(N)Cc1ccc(O)cc1)C(C)O)C(C)O)C(C)CC)C(C)CC)C(C)C)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N1CCCC1C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1CCCC1C(=O)N1CCCC1C(=O)N1CCCC1C(=O)NC(CO)C(N)=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 236
Group description: Participants received 15 mg tirzepatide administered SC once a week.
Eligibility criteria:
Inclusion Criteria:

Have been diagnosed with type 2 diabetes mellitus (T2DM)
Have HbA1c between ≥7.5% and ≤11%
Have been treated for at least 90 days prior to day of screening with once or twice daily basal insulin with or without stable dose of metformin ≥1500 mg/day and up to maximum approved dose per country specific approved label, sulfonylureas or dipeptidyl peptidase 4 inhibitors
Be of stable weight (± 5%) for at least 90 days
Have a BMI ≥23 kilograms per meter squared (kg/m²) and ≤45 kg/m² at screening

Exclusion Criteria

Have type 1 diabetes mellitus
Have had chronic or acute pancreatitis any time prior to study entry
Have proliferative diabetic retinopathy or diabetic macular edema or nonproliferative diabetic retinopathy requiring immediate or urgent treatment
Have disorders associated with slowed emptying of the stomach, have had any stomach surgeries for the purpose of weight loss, or are chronically taking drugs that directly affect gastrointestinal motility
Have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months
Have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2
Have been taking weight loss drugs, including over-the-counter medications during the last 3 months
Have an estimated glomerular filtration rate <30 mL/minute/1.73 m² [for participants on metformin, estimated glomerular filtration rate <45 mL/min/1.73 m2 (or lower than the country-specific threshold for using the protocol-required dose of metformin per local label)]
Intervention: Humalog
Trial phase: Phase 3
SMILES: CCC(C)C(NC(=O)CN)C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(N)=O)C(=O)NC1CSSCC2NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CSSCC(NC(=O)C(CC(C)C)NC(=O)C(Cc3c[nH]cn3)NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(Cc3c[nH]cn3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(C(=O)NC(CCCCN)C(=O)N3CCCC3C(=O)NC(C(=O)O)C(C)O)C(C)O)CSSCC(C(=O)NC(CC(N)=O)C(=O)O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(N)=O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(C)C)NC(=O)C(CO)NC2=O)NC1=O)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 708
Group description: Participants received Insulin lispro (U100) administered SC three times a day.
Eligibility criteria:
Inclusion Criteria:

Have been diagnosed with type 2 diabetes mellitus (T2DM)
Have HbA1c between ≥7.5% and ≤11%
Have been treated for at least 90 days prior to day of screening with once or twice daily basal insulin with or without stable dose of metformin ≥1500 mg/day and up to maximum approved dose per country specific approved label, sulfonylureas or dipeptidyl peptidase 4 inhibitors
Be of stable weight (± 5%) for at least 90 days
Have a BMI ≥23 kilograms per meter squared (kg/m²) and ≤45 kg/m² at screening

Exclusion Criteria

Have type 1 diabetes mellitus
Have had chronic or acute pancreatitis any time prior to study entry
Have proliferative diabetic retinopathy or diabetic macular edema or nonproliferative diabetic retinopathy requiring immediate or urgent treatment
Have disorders associated with slowed emptying of the stomach, have had any stomach surgeries for the purpose of weight loss, or are chronically taking drugs that directly affect gastrointestinal motility
Have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months
Have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2
Have been taking weight loss drugs, including over-the-counter medications during the last 3 months
Have an estimated glomerular filtration rate <30 mL/minute/1.73 m² [for participants on metformin, estimated glomerular filtration rate <45 mL/min/1.73 m2 (or lower than the country-specific threshold for using the protocol-required dose of metformin per local label)]
Intervention: Remdesivir
Trial phase: Phase 1 | Phase 2
ATC code: J05AB16
SMILES: CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@](C#N)(c2ccc3c(N)ncnn23)[C@H](O)[C@@H]1O)Oc1ccccc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 12
Group description: Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.
Eligibility criteria:
Key Inclusion Criteria:

Willing and able to provide written informed consent, or with a legal representative who can provide informed consent
SARS-CoV-2 infection first confirmed by polymerase chain reaction (PCR) (Parts A and B) or by nucleic acid testing or direct antigen testing (Part C) with sample collected ≤ 4 days prior to randomization
COVID-19 symptom onset ≤ 7 days prior to randomization
Oxygen saturation as measured by pulse oximetry (SpO2) > 94% on room air

Key Exclusion Criteria:

Ongoing or prior participation in any other clinical trial of an experimental vaccine or treatment for COVID-19
Prior or current hospitalization for COVID-19 or need for hospitalization

Treatment of COVID-19 with other agents with actual or possible direct antiviral activity against SARS-CoV-2 including intravenous (IV) RDV or administration of any SARS-CoV-2 (or COVID-19) vaccine

Participants chronically administered chloroquine or hydroxychloroquine for any reason are to be excluded
Requiring oxygen supplementation
Positive pregnancy test
Breastfeeding female
Known hypersensitivity to the study treatment, its metabolites, or formulation excipient
Pre-existing pulmonary conditions such as chronic obstructive pulmonary disease or asthma (Parts A and B only)

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Intervention: Remdesivir
Trial phase: Phase 1 | Phase 2
ATC code: J05AB16
SMILES: CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@](C#N)(c2ccc3c(N)ncnn23)[C@H](O)[C@@H]1O)Oc1ccccc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 61
Group description: Participants received inhaled RDV 39 mg administered daily as an aerosolized solution by inhalation through mouth piece for 5 days.
Eligibility criteria:
Key Inclusion Criteria:

Willing and able to provide written informed consent, or with a legal representative who can provide informed consent
SARS-CoV-2 infection first confirmed by polymerase chain reaction (PCR) (Parts A and B) or by nucleic acid testing or direct antigen testing (Part C) with sample collected ≤ 4 days prior to randomization
COVID-19 symptom onset ≤ 7 days prior to randomization
Oxygen saturation as measured by pulse oximetry (SpO2) > 94% on room air

Key Exclusion Criteria:

Ongoing or prior participation in any other clinical trial of an experimental vaccine or treatment for COVID-19
Prior or current hospitalization for COVID-19 or need for hospitalization

Treatment of COVID-19 with other agents with actual or possible direct antiviral activity against SARS-CoV-2 including intravenous (IV) RDV or administration of any SARS-CoV-2 (or COVID-19) vaccine

Participants chronically administered chloroquine or hydroxychloroquine for any reason are to be excluded
Requiring oxygen supplementation
Positive pregnancy test
Breastfeeding female
Known hypersensitivity to the study treatment, its metabolites, or formulation excipient
Pre-existing pulmonary conditions such as chronic obstructive pulmonary disease or asthma (Parts A and B only)

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Intervention: Betamethasone
Trial phase: Phase 2
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 29
Group description: Dexamethasone solution (0.5mg/5ml) TID swish and spit for 4 weeks

dexamethasone 0.5mg/5ml solution: Patient with oral ulcerative conditions were asked to rinse with dexamethasone 0.5mg/5ml solution three times a day for 4 weeks and expectorate
Eligibility criteria:
Inclusion Criteria:

Age 18 years and older.
Patients with symptomatic biopsy proven Oral Inflammatory Ulcerative Diseases (worst VAS sensitivity score ≥ 7 over the last week).
Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

Patients already on topical or systemic steroids.
Inability to comply with study instructions.
Uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements.
VAS sensitivity score < 7.
Pregnant women. A urine pregnancy test will be performed for women of child bearing potential.
Allergy to fluconazole.
Intervention: Prednisone
Trial phase: Phase 4
ATC code: A07EA03 | H02AB07
SMILES: [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 14
Group description: Participants randomized to the steroid arm will be given a prescription for prednisone 20mg daily for 7 days prior to surgery, otherwise, pre-operative standard of care

Prednisone: used to reduce inflammation
Eligibility criteria:
Inclusion Criteria:

Graves' disease or Hashimoto's disease with positive thyroid autoantibodies (Thyroglobulin Antibody [TgAb], Thyroid peroxidase antibody [TPO], Thyroid Stimulating Ig antibody [TSI], and/or Thyrotropin Receptor antibody [TRAb]).
Participants will be invited to join the study after the decision has been made to proceed with thyroidectomy as the clinical treatment of their autoimmune thyroid disease.

Exclusion Criteria:

Pediatric patients < 18
Prior treatment with radioactive iodine (RAI)
Known diagnosis of thyroid cancer
Diabetic patients.
Patients on any immunosuppressive regiment (such as organ transplant patients or patients treated for other autoimmune condition)
Pregnant patients.
Patients being treated for active infection.
Any patient for whom the surgeon feels steroids would provide a clear benefit (ie. Extremely high auto-antibody levels with a very large, inflamed thyroid gland) will be treated according to the clinical judgement of the surgeon. If a surgeon feels steroids are indicated and prescribes them, the patient will not be eligible for the trial.
Intervention: Telotristat
Trial phase: Phase 2
ATC code: A16AX15
SMILES: Cc1ccn(-c2cc(Cl)ccc2[C@@H](Oc2cc(-c3ccc(C[C@H](N)C(=O)O)cc3)nc(N)n2)C(F)(F)F)n1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: Participants in this group will receive 750mg Telotristat per day.

Telotristat (Low-Dose): Participants in this group will receive Lutetium Lu 177 Dotate (Lutathera) by IV every 2 months (Q8weeks) for a total of 4 doses. They will also receive oral Telotristat at 750mg per day (250mg TID) for 20 months.
Eligibility criteria:
Inclusion Criteria:

Metastatic, or unresectable, histologically confirmed well-differentiated grade 1 and 2 neuroendocrine tumor with a positive gallium 68 Dotatate scan within 6 months prior to study enrollment
Baseline CT scan or MRI with measurable progressive disease based on RECIST Criteria
Failure of at least one prior systemic cancer treatment for this diagnosis
Recovered from Adverse Events of previously administered therapeutic agents to Grade 2 or less toxicity according to CTCAE version 5.0
Eastern Cooperative Oncology Group (ECOG) performance status ≤2
normal organ and marrow function

Exclusion Criteria:

Prior exposure to Lutetium Lu 177 Dotatate
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Telotristat or Lutetium Lu 177 Dotatate.
Presence of unstable angina or myocardial infarction
New York Heart Association (NYHA) Class III or IV heart failure
uncontrolled angina
history of severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or Grade 3 conduction system abnormalities
Pregnant or lactating women
Women of childbearing potential or male patients of reproductive potential
Any other significant medical or psychiatric condition, currently uncontrolled by treatment, which may interfere with completion of the study
Intervention: Telotristat
Trial phase: Phase 2
ATC code: A16AX15
SMILES: Cc1ccn(-c2cc(Cl)ccc2[C@@H](Oc2cc(-c3ccc(C[C@H](N)C(=O)O)cc3)nc(N)n2)C(F)(F)F)n1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: Participants in this group will receive 1500mg Telotristat per day.

Telotristat (High-Dose): Participants in this group will receive Lutetium Lu 177 Dotate (Lutathera) by IV every 2 months (Q8weeks) for a total of 4 doses. They will also receive oral Telotristat at 1500mg per day (500mg TID) for 20 months.
Eligibility criteria:
Inclusion Criteria:

Metastatic, or unresectable, histologically confirmed well-differentiated grade 1 and 2 neuroendocrine tumor with a positive gallium 68 Dotatate scan within 6 months prior to study enrollment
Baseline CT scan or MRI with measurable progressive disease based on RECIST Criteria
Failure of at least one prior systemic cancer treatment for this diagnosis
Recovered from Adverse Events of previously administered therapeutic agents to Grade 2 or less toxicity according to CTCAE version 5.0
Eastern Cooperative Oncology Group (ECOG) performance status ≤2
normal organ and marrow function

Exclusion Criteria:

Prior exposure to Lutetium Lu 177 Dotatate
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Telotristat or Lutetium Lu 177 Dotatate.
Presence of unstable angina or myocardial infarction
New York Heart Association (NYHA) Class III or IV heart failure
uncontrolled angina
history of severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or Grade 3 conduction system abnormalities
Pregnant or lactating women
Women of childbearing potential or male patients of reproductive potential
Any other significant medical or psychiatric condition, currently uncontrolled by treatment, which may interfere with completion of the study
Intervention: Estradiol
Trial phase: Not Applicable
ATC code: G02BB01 | G03AA14 | G03AA17 | G03AB08 | G03CA03 | G03CA53 | G03EA01 | G03EA02 | G03EA03 | G03FA01 | G03FA02 | G03FA03 | G03FA04 | G03FA05 | G03FA06 | G03FA07 | G03FA08 | G03FA09 | G03FA10 | G03FA11 | G03FA12 | G03FA13 | G03FA14 | G03FA15 | G03FA16 | G03FA17 | G03FB01 | G03FB02 | G03FB03 | G03FB04 | G03FB05 | G03FB06 | G03FB07 | G03FB08 | G03FB09 | G03FB10 | G03FB11 | G03FB12 | G03HB01 | H01CC53 | H01CC54
SMILES: [H][C@@]12CCc3cc(O)ccc3[C@@]1([H])CC[C@]1(C)[C@@H](O)CC[C@@]21[H]
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 23
Group description: Estrace: Vaginal estrogen cream, estradiol: 100mcg
Eligibility criteria:
Inclusion Criteria:

Postmenopausal status as defined by amenorrhea for >12 months or history of bilateral salpingo-oophrectomy or if the patient has had a hysterectomy and menopausal symptoms for >1 year or FSH > 40
Symptoms of GSM
Negative Pap smear as per ASCCP guidelines
Capable of giving informed consent
Ambulatory
Capable and willing to follow all study-relation procedures

Exclusion Criteria:

Use of any HRT (systemic or local) or raloxifene within six weeks of proposed start date
History of estrogen-sensitive tumor
Undiagnosed vaginal bleeding in the past 12 months
History of thromboembolic event
Currently have or have had liver problem
Bleeding disorder
Impaired mental status
Prior pelvic irradiation
Active vaginal infection
Any medical reason the investigator deems incompatible with treatment with vaginal estrogen
Intervention: Acetylcysteine
Trial phase: Phase 1
ATC code: R05CB01 | S01XA08 | V03AB23
SMILES: CC(=O)N[C@@H](CS)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2
Group description: N-Acetyl Cysteine 600 mg three times daily

N-Acetyl cysteine: Oral N-Acetyl Cysteine
Eligibility criteria:
Inclusion Criteria:

Age > 18
performance of a SARS-CoV-2 test within 1 day of enrollment, N.B., must be positive to proceed to treatment phase of the trial

Exclusion Criteria:

All patients under 18
Known allergy to N-Acetyl Cysteine
Known allergy to famotidine or other H2-receptor antagonists
Pregnant or Nursing Mothers
Laboratory Evidence or History of Renal Impairment (eGFR < 30 mL/min/1.73 m2)
Taking H2-receptor antagonists, hydroxychloroquine or chloroquine.
Patient has been admitted to the hospital prior to study enrollment
Intervention: BENZOYL PEROXIDE
Trial phase: Phase 4
ATC code: D10AE01 | D10AE51
SMILES: O=C(OOC(=O)c1ccccc1)c1ccccc1
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 25
Group description: BPO 2.5% leave-on gel: Acne patients will be assigned to once or twice daily as tolerated.
Eligibility criteria:
Inclusion Criteria:

A confirmed diagnosis of acne that warrants initiating topical medications.
Denies use of any prescribed systemic acne treatments in the past 30 days.
Denies use of any prescribed topical medications in the past 30 days.
Denies use of any OTC topical acne medications in the past 14 days.
Denies use of any emollients in the past 24 hours (if feasible).
Denies bathing or facial washing in the past 12 hours (if feasible).
Willingness to adhere to the recommended topical regimen during the duration of the study.

Exclusion Criteria:

Women who are pregnant, breastfeeding, or planning to get pregnant during the study.
Use of any investigational drug(s) in the past 3 months.
Intervention: Fobrepodacin
Trial phase: Phase 2
SMILES: [H][C@]1(c2c(F)c(-c3cnc(C(C)(C)OP(=O)(O)O)nc3)cc3nc(NC(=O)NCC)[nH]c23)CCCO1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: SPR720 500 mg administered orally once daily for 28 days.
Eligibility criteria:
Inclusion Criteria:

Has a diagnosis of NTM-PD due to MAC
Had at least 1 prior positive culture (sputum or bronchoalveolar lavage) positive for MAC in the previous 6 months
Has an induced sputum culture at screening positive for MAC by at least one of the following methods performed by the microbiology laboratory: quantitative culture on solid agar or growth on liquid media (MGIT)
Is either treatment naïve and has not received any prior treatment for MAC, OR if previously treated for MAC, has culture evidence of persistent, recurrent, or relapsed disease and has been off therapy for at least 6 months
In the opinion of the Investigator, is ready to initiate treatment (treatment naïve) or reinitiate treatment (previously treated) within the next 3 months, and for whom a delay, in order to participate in a placebo-controlled clinical trial, is considered reasonable and clinically acceptable

Had clinical signs and symptoms within the 6 weeks before the date of consent that are consistent with NTM-PD with at least two of the following:

chronic cough
fatigue
frequent throat clearing
shortness of breath (dyspnea)
coughing up of blood (hemoptysis)
excessive mucus (sputum) production
fever
night sweats
loss of appetite
unintended weight loss
wheezing
chest pain
Has a measured forced expiratory volume in 1 second (% predicted FEV1) ≥30% on pulmonary function test within 3 months prior to consent
Has a chest radiograph (CXR) or computed tomography (CT) scan within 6 months prior to consent with findings consistent with NTM-PD. If no CXR or CT scan is available, a CXR or CT scan should be performed at screening to confirm eligibility.
Other inclusion criteria per protocol

Exclusion Criteria:

Has disseminated or extrapulmonary NTM
Has end-stage NTM-PD or treatment-refractory NTM-PD and is unlikely to respond to protocol-specified SOC treatment
Had isolation on sputum cultures of any species of Mycobacterium other than a species included in MAC within the past 6 months
Had prior isolation of MAC with macrolide resistance
Has received any systemic (oral or IV) or inhaled antibiotic with activity against MAC between consent and randomization
Has a potentially confounding underlying pulmonary disease, including but not limited to cystic fibrosis, active pulmonary malignancy (primary or metastatic), NTM-hypersensitivity disease pneumoconiosis, or another advanced lung disease with a % predicted FEV1<30%
Other exclusion criteria per protocol
Intervention: Cyclosporine
Trial phase: Phase 4
ATC code: L04AD01 | S01XA18
SMILES: CC=CCC(C)C(O)C1C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 10
Group description: 10 subjects will be receiving Restasis ophthalmic solution twice a day in both eyes

Cyclosporine: Used to increase tear production in patients who have dry eye caused by inflammation
Eligibility criteria:
Inclusion Criteria:

18 years of age or older
Signs and symptoms of Dry Eye Disease
Consent to treat with topical immunomodulator
Willing and able to comply with clinic visits and study related procedures
Willing and able to sign the informed consent form

Exclusion Criteria:

Patients under the age of 18.
Pregnancy (must be ruled out in women of child-bearing age with pregnancy test)
Active infectious systemic disease
Active infectious ocular or extraocular disease
Altered nasolacrimal flow of either acquired, induced, or congenital origin
Hypersensitivity to dexamethasone
Patients who have been on topical immunomodulating agents in the previous 3 months to their baseline visit
Patient being treated with either topical, oral, or intravenous immunosuppressive agents, immunomodulating agents, or steroid (including NSAIDS)
Patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator